Tonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Friday morning. The firm issued a sell rating on the stock.

Separately, Alliance Global Partners boosted their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a buy rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Price Performance

Tonix Pharmaceuticals stock remained flat at $0.48 during mid-day trading on Friday. 631,993 shares of the company’s stock were exchanged, compared to its average volume of 828,251. Tonix Pharmaceuticals has a 12 month low of $0.42 and a 12 month high of $32.32. The stock’s fifty day simple moving average is $1.11 and its two-hundred day simple moving average is $5.78. The company has a current ratio of 1.47, a quick ratio of 0.87 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $1.43 million, a P/E ratio of 0.00 and a beta of 2.12.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, May 13th. The company reported ($5.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.64) by $10.88. The company had revenue of $2.48 million during the quarter, compared to analyst estimates of $4.00 million. Equities research analysts expect that Tonix Pharmaceuticals will post -34.73 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,770,000 shares of the company’s stock after purchasing an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned approximately 14.09% of Tonix Pharmaceuticals worth $1,519,000 at the end of the most recent quarter. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.